内容来源：https://techcrunch.com/2026/07/14/openai-researcher-miles-wang-in-talks-to-launch-ai-drug-discovery-startup-valued-at-2b/

内容总结：

OpenAI研究员Miles Wang即将离职创业，专注于开发用于药物发现的人工智能模型。据知情人士透露，这位曾参与利用AI加速科学和生物发现的研究人员，正计划成立一家新公司，并有多位OpenAI同事有望加入。

消息人士称，Wang正在洽谈以20亿美元估值融资约2亿美元，光速创投（Lightspeed）有望领投此轮。不过谈判仍在进行中，交易尚未最终敲定，细节可能生变。Wang本人对报道中的融资金额和公司描述提出异议，但未给出具体修正信息；光速创投则未回应置评请求。

此次融资谈判反映出投资界对AI在生命科学领域突破的浓厚兴趣。就在周二，成立仅两年的AI药物发现初创公司Chai Discovery宣布以38亿美元估值完成4亿美元融资（其联合创始人Josh Meier也曾是OpenAI研究员）。此外，谷歌DeepMind孵化的Isomorphic Labs也在今年5月完成21亿美元B轮融资。

多位消息人士向TechCrunch透露，Wang的新公司或聚焦于开发AI模型，帮助现有药物（包括部分临床试验失败的药物）找到新用途。由于这类药物已通过安全性测试，探索已获批药物的新适应症，相比从零研发新药能大幅缩短盈利周期。

Wang于2024年从哈佛大学计算机科学专业辍学后加入OpenAI，期间参与合著了多篇研究论文，内容涉及评估AI模型如何实现科学发现的自动化与加速化。近年来，投资界对未完成大学学业的年轻创始人再次展现出投资热情。

中文翻译：

OpenAI研究员Miles Wang即将离职，创立一家专注于开发药物发现AI模型的新公司。据四位知情人士透露，其工作内容曾包括运用AI加速科学和生物学发现。数位OpenAI研究员预计将加入这家新创企业。
两位知情人士称，Wang正洽谈以20亿美元估值融资约2亿美元。据消息来源，Lightspeed正主导本轮融资谈判。目前谈判仍在进行中，交易可能尚未最终敲定，细节或有变动。
Wang对报道中的融资数额及公司描述提出异议，但未明确更正具体数据或细节。Lightspeed未回应置评请求。
此番融资动向反映出投资者对AI应用于生命科学突破的兴趣。成立仅两年的Chai Discovery公司——其开发预测分子相互作用以识别新药的AI模型——于周二宣布以38亿美元估值完成4亿美元融资（联合创始人Josh Meier也曾以研究员身份任职OpenAI）。与此同时，谷歌DeepMind旗下专注于药物发现AI模型的Isomorphic Labs于五月完成21亿美元B轮融资。
多位消息人士向TechCrunch透露，Wang的新公司或致力于开发AI模型，帮助现有药物（及可能曾在临床试验中失败的药物）找到新用途。为FDA已批准药物寻找新适应症，能比从零研发新药更快实现盈利，因其安全性已验证。
Wang于2024年从哈佛大学计算机科学本科退学后加入OpenAI（近年来，投资者重新乐于押注未完成大学学业的年轻创始人）。
在OpenAI期间，他合著了多篇研究论文，内容涉及评估AI模型如何实现科学发现的自动化与加速。

英文来源：

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.
Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.
Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.
The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.
Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.
Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)
At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.